Rand Redwan Al Sari, Husna Irfan Thalib, Syeda Sobiah Imad, Sariya Khan, Shyma Haidar, Bayan Mohammed Khair Al Zoabi, Sahar Hamed Fadda, Samratul Fuadah, Hassan Abu Alwan, Abdullah Alghobaishi
{"title":"单胺类神经递质转运障碍的比较研究:机制、临床表现和治疗方法。","authors":"Rand Redwan Al Sari, Husna Irfan Thalib, Syeda Sobiah Imad, Sariya Khan, Shyma Haidar, Bayan Mohammed Khair Al Zoabi, Sahar Hamed Fadda, Samratul Fuadah, Hassan Abu Alwan, Abdullah Alghobaishi","doi":"10.25122/jml-2024-0398","DOIUrl":null,"url":null,"abstract":"<p><p>Neurotransmitters play important roles in brain function, influencing cognition, movement, and behavior. Disruption in neurotransmitter biosynthesis, expression, transport, or function due to genetic mutations can lead to various neurological and psychiatric disorders with variable age of onset. Catecholamines like dopamine, norepinephrine, epinephrine, and serotonin are key monoamines transported by specific transporters, including the dopamine transporter (DAT) and the vesicular monoamine transporter 2 (VMAT2). Disorders that involve monoamine neurotransmitter transport include dopamine transporter deficiency syndrome (DTDS) and brain dopamine-serotonin vesicular disorders (PKDYS2). These rare syndromes manifest with movement disorders and neuropsychiatric symptoms. DTDS results from a mutation in the <i>SLC6A3</i> gene affecting dopamine reuptake, while PKDYS2 involves a mutation in the <i>SLC18A2</i> gene impairing the transport of dopamine and serotonin. This review provides a comparative analysis of the diagnostic approaches, the management strategies, and the outcomes for these distinct disorders.</p>","PeriodicalId":16386,"journal":{"name":"Journal of Medicine and Life","volume":"18 3","pages":"188-195"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12022732/pdf/","citationCount":"0","resultStr":"{\"title\":\"A comparative exploration of monoamine neurotransmitter transport disorders: mechanisms, clinical manifestations, and therapeutic approaches.\",\"authors\":\"Rand Redwan Al Sari, Husna Irfan Thalib, Syeda Sobiah Imad, Sariya Khan, Shyma Haidar, Bayan Mohammed Khair Al Zoabi, Sahar Hamed Fadda, Samratul Fuadah, Hassan Abu Alwan, Abdullah Alghobaishi\",\"doi\":\"10.25122/jml-2024-0398\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Neurotransmitters play important roles in brain function, influencing cognition, movement, and behavior. Disruption in neurotransmitter biosynthesis, expression, transport, or function due to genetic mutations can lead to various neurological and psychiatric disorders with variable age of onset. Catecholamines like dopamine, norepinephrine, epinephrine, and serotonin are key monoamines transported by specific transporters, including the dopamine transporter (DAT) and the vesicular monoamine transporter 2 (VMAT2). Disorders that involve monoamine neurotransmitter transport include dopamine transporter deficiency syndrome (DTDS) and brain dopamine-serotonin vesicular disorders (PKDYS2). These rare syndromes manifest with movement disorders and neuropsychiatric symptoms. DTDS results from a mutation in the <i>SLC6A3</i> gene affecting dopamine reuptake, while PKDYS2 involves a mutation in the <i>SLC18A2</i> gene impairing the transport of dopamine and serotonin. This review provides a comparative analysis of the diagnostic approaches, the management strategies, and the outcomes for these distinct disorders.</p>\",\"PeriodicalId\":16386,\"journal\":{\"name\":\"Journal of Medicine and Life\",\"volume\":\"18 3\",\"pages\":\"188-195\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12022732/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medicine and Life\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.25122/jml-2024-0398\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicine and Life","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25122/jml-2024-0398","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
A comparative exploration of monoamine neurotransmitter transport disorders: mechanisms, clinical manifestations, and therapeutic approaches.
Neurotransmitters play important roles in brain function, influencing cognition, movement, and behavior. Disruption in neurotransmitter biosynthesis, expression, transport, or function due to genetic mutations can lead to various neurological and psychiatric disorders with variable age of onset. Catecholamines like dopamine, norepinephrine, epinephrine, and serotonin are key monoamines transported by specific transporters, including the dopamine transporter (DAT) and the vesicular monoamine transporter 2 (VMAT2). Disorders that involve monoamine neurotransmitter transport include dopamine transporter deficiency syndrome (DTDS) and brain dopamine-serotonin vesicular disorders (PKDYS2). These rare syndromes manifest with movement disorders and neuropsychiatric symptoms. DTDS results from a mutation in the SLC6A3 gene affecting dopamine reuptake, while PKDYS2 involves a mutation in the SLC18A2 gene impairing the transport of dopamine and serotonin. This review provides a comparative analysis of the diagnostic approaches, the management strategies, and the outcomes for these distinct disorders.
期刊介绍:
The Journal of Medicine and Life publishes peer-reviewed articles from various fields of medicine and life sciences, including original research, systematic reviews, special reports, case presentations, major medical breakthroughs and letters to the editor. The Journal focuses on current matters that lie at the intersection of biomedical science and clinical practice and strives to present this information to inform health care delivery and improve patient outcomes. Papers addressing topics such as neuroprotection, neurorehabilitation, neuroplasticity, and neuroregeneration are particularly encouraged, as part of the Journal''s continuous interest in neuroscience research. The Editorial Board of the Journal of Medicine and Life is open to consider manuscripts from all levels of research and areas of biological sciences, including fundamental, experimental or clinical research and matters of public health. As part of our pledge to promote an educational and community-building environment, our issues feature sections designated to informing our readers regarding exciting international congresses, teaching courses and relevant institutional-level events.